These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2592584)

  • 21. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.
    Wiesel FA; Alfredsson G; Ehrnebo M; Sedvall G
    Eur J Clin Pharmacol; 1980 May; 17(5):385-91. PubMed ID: 7418717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism.
    Frey FJ; Frey BM
    J Lab Clin Med; 1983 Apr; 101(4):593-604. PubMed ID: 6833830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition and metabolism of carbovir in mice dosed intravenously or orally.
    el Dareer SM; Tillery KF; Rose LM; Struck RF; Hill DL
    Drug Metab Dispos; 1990; 18(6):842-5. PubMed ID: 1981526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prednisolone metabolism and excretion in the isolated perfused rat kidney.
    Rocci ML; Szefler SJ; Acara M; Jusko WJ
    Drug Metab Dispos; 1981; 9(3):177-82. PubMed ID: 6113924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of ketoconazole on the metabolism of prednisolone.
    Zürcher RM; Frey BM; Frey FJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):366-72. PubMed ID: 2639662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
    Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
    J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). I. Absorption, distribution, metabolism and excretion in rats].
    Suzuki T; Serizawa K; Somiya Y; Shirai M; Endo S; Morishita M
    Jpn J Antibiot; 1987 Jan; 40(1):188-201. PubMed ID: 3586328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enantioselective disposition of salbutamol in man following oral and intravenous administration.
    Boulton DW; Fawcett JP
    Br J Clin Pharmacol; 1996 Jan; 41(1):35-40. PubMed ID: 8824691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ketanserin in man.
    Reimann IW; Okonkwo PO; Klotz U
    Eur J Clin Pharmacol; 1983; 25(1):73-6. PubMed ID: 6617728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-dependent pharmacokinetic study on caffeic acid in rabbits after intravenous administration.
    Uang YS; Hsu KY
    Biopharm Drug Dispos; 1997 Nov; 18(8):727-36. PubMed ID: 9373729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of prednisolone in normal and asthmatic subjects in relation to dose.
    McAllister WA; Winfield CR; Collins JV
    Eur J Clin Pharmacol; 1981; 20(2):141-5. PubMed ID: 7262175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution and metabolism of prednisone in mice, dogs, and monkeys.
    El Dareer SM; Struck RF; White VM; Mellett LB; Hill DL
    Cancer Treat Rep; 1977 Oct; 61(7):1279-89. PubMed ID: 412589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal elimination and metabolism of etofenamate in volunteers after administration of various doses].
    Dell HD; Beckermann B; Fiedler J; Kamp R
    Arzneimittelforschung; 1990 Mar; 40(3):311-6. PubMed ID: 2346542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.